Authors
Latest:
Initial Efficacy and Safety of RP1 + Nivolumab in Patients With Anti–PD-1–Failed Melanoma From the Ongoing Phase 1/2 IGNYTE StudyExpert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.
Latest:
Dr Birrer on the Potential Utility of ADCs in Platinum-Resistant Ovarian CancerMichael J. Birrer, MD, PhD, discusses how the expansion of antibody-drug conjugates can address the need for more effective regimens in platinum-resistant ovarian cancer.
Latest:
Dr. Bouvet Discusses Risk Factors for Thyroid CancerMichael Bouvet, MD, professor of surgery, University of California, San Diego, discusses risk factors for thyroid cancer.
Latest:
Dr. Brawer on the Results of the Prolaris Test for Patients Prostate CancerMichael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the results of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
Latest:
Management of Patients with CancerMichael Broderson, PharmD, Nebraska Cancer Specialists, discusses the management of patients with cancer.
Latest:
Dr Choi on the Implications of Approving Liso-Cel in Patients With CLLMichael Choi, MD, discusses the potential FDA approval of lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia.
Latest:
Dr. Choi on the Long-Term Efficacy of Frontline Ibrutinib in CLLMichael Choi, MD, discusses the long-term efficacy of ibrutinib given as a frontline treatment in chronic lymphocytic leukemia.
Latest:
Dr. Cookson on Understanding Predictive Features in the Management of Prostate CancerMichael S. Cookson, MD, MMHC, discusses how understanding the relationship between key predictive factors and disease progression can help better inform the overall management of prostate cancer.
Latest:
Tech Sectors: Biotechnology: The Treatment of Palmar-plantar ErythrodysesthesiaA potential new candidate uses uracil to combat this cancer treatment side effect.
Latest:
Dr. Mix on Local Consolidative Therapy in Oligometastatic NSCLCMichael D. Mix, MD, assistant professor of radiation oncology at Upstate University Hospital, discusses the use of local consolidative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).
Latest:
Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLCMichael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.
Latest:
Dr. Duruisseaux on the Incidence of NRG1 Fusions in Solid TumorsMichaël Duruisseaux, MD, a medical oncologist at Lyon Cancer Institute in France, discusses the incidence of NRG1 fusions in solid tumors.
Latest:
Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell Therapy in Solid TumorsMichael Hurwitz, MD, PhD, discusses the ongoing investigation into the use of CAR T-cell therapies in patients with solid tumors, such as kidney cancers.
Latest:
Dr. Michael Williams on Treating Subtypes of MCLMichael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses personalized medicine in mantle cell lymphoma (MCL).
Latest:
Michael Eckenfels on Bortezomib Delivery Route ChangesMichael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.
Latest:
Stereotactic Radiation Potential Emerges in Prostate CancerStereotactic ablative radiosurgery, which is administered in far fewer but larger doses than conventional radiotherapy, has the potential to benefit a substantial proportion of patients with low-, intermediate-, and potentially even high-risk prostate cancers.
Latest:
Dr. Michael Gnant on the PAM50 Breast Cancer Intrinsic SubtypesMichael Gnant, MD, professor of the Department of Surgery at the Medical University of Vienna in Vienna, Austria, discusses the four intrinsic subtypes of the PAM50 recurrence score test and a clinical trial comparing this test with OncotypeDX.
Latest:
Dr. Green on Treatment Regimens for Patients With Multiple Myeloma in Early RelapseMichael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.
Latest:
Informed Patients Are More Likely to Choose Palliative CareResearch from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.
Latest:
Hepatic Infusion Can Convert CRC Liver Metastases to Operable StateOverall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.
